EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $39 from $38 and keeps an Equal Weight rating on the shares. The company’s ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Key Takeaways Moderna reported a larger loss than analysts had expected for the fourth quarter on Friday.The COVID vaccine ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss. Revenue came in at $966 million, below the consensus forecast of $995.44 ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...